Real-world outcomes of COVID-19 treatment with remdesivir in a Spanish hospital

Remdesivir is the only antiviral approved for lower respiratory tract infection produced by SARS-CoV-2. The main objective of this study was to determine the mortality rate, readmissions, mean hospital stay, need for higher levels of oxygen support, and adverse effect-induced abandonment rate in hos...

Descripción completa

Detalles Bibliográficos
Autores principales: Hidalgo-Tenorio, Carmen, García-Vallecillos, Coral, Sequera-Arquelladas, Sergio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
4900
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448042/
https://www.ncbi.nlm.nih.gov/pubmed/34664862
http://dx.doi.org/10.1097/MD.0000000000027228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448042/
https://www.ncbi.nlm.nih.gov/pubmed/34664862
http://dx.doi.org/10.1097/MD.0000000000027228

Ejemplares similares